Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

(NASDAQ:STTK), – Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325 in Q3 2025 – – Cash balance of approximately $50.5 million at end of Q2 […]

Hyperscale Data Subsidiary askROI Launches OnlyBulls — a Mobile-Only Investing App with Your Own AI Market Agent

Hyperscale Data, Inc.(NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the launch ofOnlyBulls, an app created and implemented by askROI, Inc., a wholly owned indirect subsidiary of Hyperscale Data (“askROI”). OnlyBulls is a mobile-only artificial intelligence (“AI”) powered companion app for portfolio management that gives every user their own

Allot Announces Second Quarter 2025 Financial Results

Exceptionally strong 73% year-over-year growth in SECaaS ARR; raising full year guidance Allot Ltd.(NASDAQ: ALLT) (TASE: ALLT), a leading global provider of innovative network intelligence and security solutions for service providers and enterprises worldwide, today announced its unaudited financial results for the second quarter 2025. https://mma.prnewswire.com/media/703889/Allot_Logo.jpg Financial Highlights for the Second Quarter of 2025 —

Landmark Clinical Study Published in Spine Demonstrates Superiority of Tissue-Sparing Circumferential Cervical Fusion Over ACDF Alone in Multilevel Cervical Fusion Surgery

Providence Medical Technology announces publication of initial FUSE study results in Spine, a leading journal for spine surgery. The journal presents peer-reviewed results of a pivotal, multicenter randomized controlled trial showing that tissue-sparing circumferential cervical fusion (CCF) significantly outperforms anterior cervical discectomy and fusion (ACDF) alone in treating three-level degenerative disc disease (DDD). The findings

Permanent Magnet Market worth $88.51 billion by 2030 – Exclusive Report by MarketsandMarkets™

The report”Permanent Magnet Marketby Type (NdFeB, SmCo, Ferrite, AlNiCo), Operating Temperature (Standard, High, Ultra-High), Manufacturing Process (Sintered, Bonded), End-use Industry, and Region – Global Forecast to 2030″,permanent magnet market is projected to reach USD 88.51 billion by 2030, from USD 58.87 billion in 2025, with a CAGR of 8.5%. https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg Browse in-depth TOC on “Permanent

Yunji to Report 2025 Interim Financial Results on August 21, 2025

Yunji Inc. (“Yunji” or the “Company”) (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced thatit plans to release its unaudited interim financial results before the market opens on Thursday, August 21, 2025. The earnings release will be available on the Company's investor relations website athttps://investor.yunjiglobal.com/. The Company will hold a conference call on

NOV Declares Regular Quarterly Dividend

NOV Declares Regular Quarterly Dividend GlobeNewswire August 14, 2025 HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — NOV Inc. (NYSE: NOV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.075 per share of common stock, payable on September 26, 2025 to each stockholder of record on September 12, 2025. About

U.S. and Australia Support for Nova’s Estelle Project

U.S. and Australia Support for Nova's Estelle Project GlobeNewswire August 14, 2025 Anchorage Alaska, Aug. 14, 2025 (GLOBE NEWSWIRE) — Nova Minerals Limited (“Nova” or the “Company”) (NASDAQ: NVA) (ASX: NVA) (FRA: QM3) ) is pleased to provide an update where both Alaska State government officials and the Australian Consular-General have shown strong support for

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire August 14, 2025 – Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial for SL-325

Aeries Technology Reports Record Q1 FY2026 Results: Cash Flow Positive, $17M Net Income Turnaround, and Strongest Start to a Fiscal Year in Company History

Aeries Technology Reports Record Q1 FY2026 Results: Cash Flow Positive, $17M Net Income Turnaround, and Strongest Start to a Fiscal Year in Company History Operational Discipline, Focus on Core Offerings, and AI-Enabled GCC Delivery Help to Drive Sustainable, Profitable Growth GlobeNewswire August 14, 2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — Aeries Technology, Inc.

Scroll to Top